The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 27, 2022

Primary Completion Date

January 6, 2025

Study Completion Date

January 24, 2025

Conditions

Type 2 DiabetesObesity

Interventions

DRUG

Semaglutide 1.34 MG/ML [Ozempic]

Semaglutide 1.34 mg/ml

DRUG

Glucose-dependent insulinotropic polypeptide (GIP)

GIP

OTHER

Semaglutide 1.34 mg/ml placebo

Saline

OTHER

GIP placebo

Saline

Trial Locations (1)

Center for Clinical Metabolic Research, Gentofte Hospital, Hellerup

All Listed Sponsors

lead

Asger Lund, MD

OTHER